Study of Postprandial Incretin Response in Women With Gestational Diabetes
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The researchers investigated nineteen pregnant women in third trimester and again postpartum. At the experimental days we performed a mealtest and drew blood for analyses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), insulin, C-peptide and glucagon.
The researchers aimed to investigate whether women with gestational diabetes mellitus exhibit decreased postprandial GLP-1 responses, and if so, whether this deficiency ceases following delivery when normal glucose tolerance is reestablished.
| Condition | Intervention |
|---|---|
|
Gestational Diabetes Mellitus |
Other: Meal test |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Reduced Postprandial GLP-1 Response in Gestational Diabetes Mellitus: a Fully Reversible Phenomenon |
Blood Plasma
| Enrollment: | 19 |
| Study Start Date: | March 2007 |
| Study Completion Date: | July 2008 |
| Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Gestational Diabetes Mellitus
Women with Gestational Diabetes Mellitus
|
Other: Meal test
Liquid meal test
|
|
Normal Glucose Tolerance
Women with Normal Glucose Tolerance
|
Other: Meal test
Liquid meal test
|
Detailed Description:
The researchers investigated nineteen pregnant women in third trimester and again postpartum. At the experimental days we performed a mealtest and drew blood for analyses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), insulin, C-peptide and glucagon.
The researchers aimed to investigate whether women with gestational diabetes mellitus exhibit decreased postprandial GLP-1 responses, and if so, whether this deficiency ceases following delivery when normal glucose tolerance is reestablished.
Eligibility| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Healthy pregnant woman were examined with a 75 g oral glucose tolerance test. Subjects with plasma glucose (PG) values at 120 min >9.0 mmol/l were diagnosed with gestational diabetes and subjects with PG <9.0 mmol/l were enrolled as healthy controls.
Inclusion Criteria:
- Normal haemoblobin
- Willingness to participate
Exclusion Criteria:
- First degree relative with diabetes
- Diabetes before pregnancy
- Positive islet cell- and GAD-65 autoantibodies
Contacts and Locations| Denmark | |
| Department of Internal Medicine, Glostrup Hospital | |
| Glostrup, Denmark, 2600 | |
| Principal Investigator: | Filip K Knop, MD PhD | Diabetes Research Division, Gentofte Hopsital |
More Information
No publications provided
| Responsible Party: | Filip K. Knop, MD PhD, Department of Internal Medicine F, University Hospital, Gentofte, Copenhagen |
| ClinicalTrials.gov Identifier: | NCT01274052 History of Changes |
| Other Study ID Numbers: | KA-060015 |
| Study First Received: | January 10, 2011 |
| Last Updated: | January 10, 2011 |
| Health Authority: | Denmark: Ethics Committee |
Keywords provided by University Hospital, Gentofte, Copenhagen:
|
Gestational diabetes mellitus Meal test Incretin hormones Glucagon-like peptide-1 (GLP-1) |
Glucose-dependent insulinotropic polypeptide Insulin C-peptide Glucagon |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes, Gestational Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Pregnancy Complications Gastric Inhibitory Polypeptide |
Incretins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions Gastrointestinal Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on October 18, 2012
